Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-cash Items (2018 - 2025)

Revolution Medicines (RVMD) has 7 years of Non-cash Items data on record, last reported at $208.4 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 24.58% year-over-year to $208.4 million; the TTM value through Dec 2025 reached $208.4 million, down 24.58%, while the annual FY2025 figure was $208.4 million, 24.58% down from the prior year.
  • Non-cash Items reached $208.4 million in Q4 2025 per RVMD's latest filing, up from $177.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $276.3 million in Q4 2024 and bottomed at $44.4 million in Q3 2021.
  • Average Non-cash Items over 5 years is $111.2 million, with a median of $84.6 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: plummeted 49.15% in 2021, then soared 140.27% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $84.0 million in 2021, then rose by 1.46% to $85.2 million in 2022, then soared by 35.02% to $115.0 million in 2023, then skyrocketed by 140.27% to $276.3 million in 2024, then fell by 24.58% to $208.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $208.4 million in Q4 2025, $177.7 million in Q3 2025, and $178.5 million in Q2 2025.